Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jianchang Lin

Showing results (61-70 of 72) with videos related to

Pageof 8
Sort By:
Leukemia|March 24, 2018
Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1Laurent Garderet, Jacob P Laubach, Anne-Marie Stoppa, et al.
Haematologica|July 29, 2017
Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone <i>vs</i>. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1María-Victoria Mateos, Tamas Masszi, Norbert Grzasko, et al.
Investigational New Drugs|March 18, 2015
Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignanciesDavid C Smith, Thea Kalebic, Jeffrey R Infante, et al.
British Journal of Haematology|May 10, 2017
Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myelomaShaji Kumar, Philippe Moreau, Parameswaran Hari, et al.
JAMA Oncology|October 14, 2021
Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical TrialCaicun Zhou, Suresh S Ramalingam, Tae Min Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 29, 2025
First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With <i>EGFR</i> Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 TrialPasi A Jänne, Bin-Chao Wang, Byoung Chul Cho, et al.
European Journal of Cancer (Oxford, England : 1990)|August 12, 2025
Fruquintinib in less pretreated patients: Multivariate profile-matching analysis of FRESCO-2 to FRESCOArvind Dasari, Cathy Eng, Sara Lonardi, et al.
Expert Review of Anticancer Therapy|December 20, 2022
Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for <i>EGFR</i> exon 20 insertion-positive non-small cell lung cancerJames Chih-Hsin Yang, Caicun Zhou, Pasi A Jänne, et al.
European Journal of Haematology|March 8, 2020
c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myelomaAlessandra Di Bacco, Nizar J Bahlis, Nikhil C Munshi, et al.
Blood|October 22, 2017
Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patientsHervé Avet-Loiseau, Nizar J Bahlis, Wee-Joo Chng, et al.
Pageof 8

Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
Leukemia|March 24, 2018
Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1Laurent Garderet, Jacob P Laubach, Anne-Marie Stoppa, et al.
Haematologica|July 29, 2017
Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone <i>vs</i>. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1María-Victoria Mateos, Tamas Masszi, Norbert Grzasko, et al.
Investigational New Drugs|March 18, 2015
Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignanciesDavid C Smith, Thea Kalebic, Jeffrey R Infante, et al.
British Journal of Haematology|May 10, 2017
Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myelomaShaji Kumar, Philippe Moreau, Parameswaran Hari, et al.
JAMA Oncology|October 14, 2021
Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical TrialCaicun Zhou, Suresh S Ramalingam, Tae Min Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 29, 2025
First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With <i>EGFR</i> Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 TrialPasi A Jänne, Bin-Chao Wang, Byoung Chul Cho, et al.
European Journal of Cancer (Oxford, England : 1990)|August 12, 2025
Fruquintinib in less pretreated patients: Multivariate profile-matching analysis of FRESCO-2 to FRESCOArvind Dasari, Cathy Eng, Sara Lonardi, et al.
Expert Review of Anticancer Therapy|December 20, 2022
Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for <i>EGFR</i> exon 20 insertion-positive non-small cell lung cancerJames Chih-Hsin Yang, Caicun Zhou, Pasi A Jänne, et al.
European Journal of Haematology|March 8, 2020
c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myelomaAlessandra Di Bacco, Nizar J Bahlis, Nikhil C Munshi, et al.
Blood|October 22, 2017
Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patientsHervé Avet-Loiseau, Nizar J Bahlis, Wee-Joo Chng, et al.
Pageof 8